Longevity Health Holdings (XAGE) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Nov 2, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q2 FY2026, filed Aug 14, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the XAGE SEC filings page.
Longevity Health Holdings (XAGE) reported $1.9M in revenue for fiscal year 2025, up 3701.4% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 5 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Revenue finally reached a measurable scale in FY2025, but losses, cash use, and liabilities still dominate the operating model.
Revenue rose from$50K in FY2024 to$1.9M in FY2025, but that scale-up came from a very small base. Gross margin fell 30.1 percentage points to57.2% while operating cash flow remained negative at-$3.3M , showing that greater activity had not yet produced better operating economics or cash conversion.
Short-term liquidity is structurally tight: current liabilities were
The cost structure is development-heavy rather than asset-heavy: research and development consumed
Financial Health Signals
We do not publish a peer-relative financial health score for Longevity Health Holdings, because the score only covers companies whose filings and listing give us what it needs to compare them with their peers. The signals and metrics below are current.
Longevity Health Holdings scores -56.92, below the 1.81 distress threshold. The score is pulled down most by an accumulated deficit of $75.8M against total assets of $2.4M. This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Longevity Health Holdings passes 4 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 1 of 3 profitability signals pass, all 2 leverage/liquidity signals pass, 1 of 2 operating efficiency signals passes.
Longevity Health Holdings reported a net loss of $6.9M while operations used $3.3M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Longevity Health Holdings reported an operating loss of $7.1M against $18K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
Longevity Health Holdings generated $396K in revenue in Q2 2026. This represents a decrease of 21.4% from the same quarter a year earlier. Against the prior quarter it is up 1.1%.
Longevity Health Holdings's EBITDA was -$711K in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Longevity Health Holdings reported a net loss of $1.9M in Q2 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Not reported for Q2 2026.
Cash & Balance Sheet
Longevity Health Holdings held $35K in cash as of Q2 2026; no long-term debt figure is on record for that period.
Not reported for Q2 2026.
Not reported for Q2 2026.
Margins & Returns
Longevity Health Holdings's gross margin was 59.5% in Q2 2026, indicating the percentage of revenue retained after direct costs. This is down 0.6 percentage points from the same quarter a year earlier. Against the prior quarter it is down 1.0 percentage points.
Not shown for Q2 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Not shown for Q2 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Not reported for Q2 2026.
Capital Allocation
Longevity Health Holdings invested $73K in research and development in Q2 2026. This represents a decrease of 67.9% from the same quarter a year earlier. Against the prior quarter it is up 32.2%.
Not reported for Q2 2026.
Not reported for Q2 2026.
XAGE Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Revenue | $396K-21.4% | $392K-23.2% | $473K+2606.0% | $426K+1975.5% | $504K+3987.8% | $510Kn/m | $17K | $21Kn/m |
| Cost of Revenue | $160K-20.2% | $155K-35.7% | $205K+16648.2% | $171K+3441.3% | $201K+68719.9% | $241Kn/m | $1K | $5Kn/m |
| Gross Profit | $236K-22.2% | $237K-12.2% | $268K+1547.7% | $254K+1523.0% | $303K+2416.3% | $270Kn/m | $16K | $16Kn/m |
| R&D Expenses | $73K-67.9% | $55K-71.8% | $135K-28.4% | $228K-31.3% | $229K+119.7% | $197K-54.1% | $189K | $332K-79.1% |
| SG&A Expenses | $873K-54.3% | N/A | N/A | N/A | $1.9M | N/A | N/A | N/A |
| Operating Income | -$724Kn/m | -$1.3Mn/m | -$2.3Mn/m | -$1.5Mn/m | -$1.9Mn/m | -$1.5Mn/m | -$1.0Mn/m | -$1.4Mn/m |
| EBITDA | -$711Kn/m | -$1.3Mn/m | -$2.3M | -$1.5Mn/m | -$1.8Mn/m | -$1.5Mn/m | N/A | -$1.4Mn/m |
| Interest Expense | $2K-15.9% | $3K-30.9% | $6K | $5K-29.0% | $3K-21.5% | $5K-56.8% | N/A | $7K-60.8% |
| Income Tax | $0n/m | $0n/m | $36Kn/m | $0n/m | $0n/m | $0n/m | -$97Kn/m | $0n/m |
| Net Income | -$1.9Mn/m | -$1.4Mn/m | -$2.1M | -$1.4Mn/m | -$1.9Mn/m | -$1.5Mn/m | N/A | -$2.9Mn/m |
| EPS (Basic) | -$0.76n/m | -$0.75 | -$1.15 | -$0.83 | -$1.56 | -$1.52 | -$0.05 | -$4.13 |
| EPS (Diluted) | N/A | -$0.75 | -$1.15 | -$0.83 | -$1.56 | -$1.52 | -$0.05 | -$4.13 |
| Diluted Shares (Avg) | N/A | 2M | N/A | 2M | 1M | 991,210 | N/A | 696,847 |
XAGE Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $1.1M-71.6% | $1.6M-50.8% | $2.4M+60.6% | $3.3M+35.1% | $3.7M-26.1% | $3.3M-46.0% | $1.5M-97.7% | $2.4M-97.0% |
| Current Assets | $712K-78.0% | $1.3M-54.8% | $2.0M+104.1% | $2.8M+50.9% | $3.2M-21.0% | $2.8M-46.2% | $956K-98.5% | $1.9M-95.2% |
| Cash & Equivalents | $35K-97.7% | $313K-59.3% | $707K+349.8% | $1.1M-2.5% | $1.6M-29.4% | $770K-13.7% | $157K-94.6% | $1.1M-85.7% |
| Short-Term Investments | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m |
| Inventory | $607K-48.3% | $735K-46.7% | $963K+785.9% | $1.0M+935.2% | $1.2M+929.8% | $1.4M | $109Kn/m | $98K-99.0% |
| Accounts Receivable | $20K-64.1% | $49K-48.6% | $37K+791.1% | $47K | $54K | $95K | $4Kn/m | N/A |
| Long-Term Investments | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m |
| Total Liabilities | $9.8M+30.8% | $8.5M+19.5% | $8.2M+33.1% | $7.3M+11.8% | $7.5M+16.4% | $7.1M-5.7% | $6.2M-84.2% | $6.5M-89.4% |
| Current Liabilities | $9.6M+38.8% | $8.3M+26.5% | $7.9M+34.7% | $6.8M+10.8% | $6.9M+19.7% | $6.6M-4.4% | $5.9M-84.7% | $6.2M-83.6% |
| Non-Current Liabilities | $162K-70.3% | $188K-65.4% | $318K+2.5% | $435K+30.9% | $543K-13.5% | $544K-18.4% | $310K-55.6% | $333K-98.6% |
| Total Equity | -$8.7Mn/m | -$6.9Mn/m | -$5.9Mn/m | -$4.0Mn/m | -$3.7Mn/m | -$3.8Mn/m | -$4.7M-119.0% | -$4.1M-119.4% |
| Retained Earnings | -$79.1Mn/m | -$77.2Mn/m | -$75.8Mn/m | -$73.7Mn/m | -$72.3Mn/m | -$70.4Mn/m | -$68.9Mn/m | -$68.0Mn/m |
Not reported in any period shown, so not listed: Goodwill, Long-Term Debt.
XAGE Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$224Kn/m | -$485Kn/m | -$306Kn/m | -$1.4Mn/m | -$836Kn/m | -$753Kn/m | -$772Kn/m | -$907Kn/m |
| Depreciation & Amortization | $13K-39.9% | $15K-37.2% | $16K-11.8% | $16K-9.5% | $22K-5.7% | $24K+1.8% | $18K-21.8% | $18K-22.4% |
| Stock-Based Compensation | $79K-59.5% | $146K+27.1% | N/A | $190K+2.3% | $194K+18.7% | $115K-45.7% | N/A | $186K-21.9% |
| Capital Expenditures | N/A | N/A | $1 | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow | N/A | N/A | -$306K | N/A | N/A | N/A | N/A | N/A |
| Investing Cash Flow | N/A | N/A | -$1n/m | $776n/m | -$15Kn/m | -$150Kn/m | $0n/m | $0n/m |
| Financing Cash Flow | -$54K-103.3% | $92K-93.9% | -$96Kn/m | $991Kn/m | $1.6M-33.2% | $1.5Mn/m | -$208Kn/m | -$154K-101.4% |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
XAGE Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 59.5%-0.6pp | 60.5%+7.6pp | 56.6%-36.4pp | 59.8%-16.7pp | 60.1%-37.5pp | 52.9% | 93.0% | 76.4% |
| Operating Margin | -182.9% | -339.1% | -480.2% | -345.4% | -369.1% | -295.2% | -5760.5% | -6919.4% |
| Net Margin | -475.6% | -365.4% | -440.4% | -335.7% | -374.6% | -295.1% | N/A | -14028.4% |
| Return on Assets | -178.5%-127.7pp | -87.2%-42.1pp | -88.0% | -43.3%+74.5pp | -50.7%+14.9pp | -45.1%+7.8pp | N/A | -117.9%-103.9pp |
| Current Ratio | 0.07-0.4x | 0.15-0.3x | 0.25+0.1x | 0.42+0.1x | 0.47-0.2x | 0.42-0.3x | 0.16-1.5x | 0.31-0.7x |
| Asset Turnover | 0.38+0.2x | 0.24+0.1x | 0.20+0.2x | 0.13+0.1x | 0.14+0.1x | 0.15+0.2x | 0.01 | 0.010.0x |
| FCF Margin | N/A | N/A | -64.8% | N/A | N/A | N/A | N/A | N/A |
Not reported in any period shown, so not listed: Return on Equity, Debt-to-Equity, Liabilities-to-Equity.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin.
Note: Shareholder equity is negative (-$5.9M), which causes the debt-to-equity, liabilities-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Note: The current ratio is below 1.0 (0.25), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it. Market cap is stated at each company's latest close.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Longevity Health Holdings XAGE | FY2025 | $1.9M | -$6.9M | N/A | $275K | — |
| Skinvisible Inc SKVI | FY2025 | $20K | N/A | N/A | $844K | — |
| PURE Bioscience PURE | FY2026 | $2.3M | -$2.5M | N/A | $9.6M | — |
Where Longevity Health Holdings Ranks
Frequently Asked Questions
Longevity Health Holdings (XAGE) reported $1.9M in total revenue for fiscal year 2025. This represents a 3701.4% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
Longevity Health Holdings (XAGE) revenue grew by 3701.4% year-over-year, from $50K to $1.9M in fiscal year 2025.
No, Longevity Health Holdings (XAGE) reported a net loss of $6.9M in fiscal year 2025.
Longevity Health Holdings (XAGE) had EBITDA of -$7.0M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
Longevity Health Holdings (XAGE) had a gross margin of 57.2% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
Longevity Health Holdings (XAGE) recorded an outflow of $3.3M in free cash flow during fiscal year 2025. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
Longevity Health Holdings (XAGE) recorded an outflow of $3.3M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
Longevity Health Holdings (XAGE) had $2.4M in total assets as of fiscal year 2025, including both current and long-term assets.
Longevity Health Holdings (XAGE) invested $14K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
Longevity Health Holdings (XAGE) invested $789K in research and development during fiscal year 2025.
Longevity Health Holdings (XAGE) had a current ratio of 0.25 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.
Longevity Health Holdings (XAGE) had a return on assets of -291.7% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
Longevity Health Holdings (XAGE) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to June 30, 2026). The market capitalization is $275K as of Nov 2, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
Longevity Health Holdings (XAGE) trades at 0.2x sales, its market capitalization divided by $1.7M revenue, trailing 12 months to June 30, 2026. The market capitalization is $275K as of Nov 2, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
At the end of fiscal year 2025, Longevity Health Holdings (XAGE) held $707K in cash, cash equivalents and investments, and reported an operating cash outflow of $3.3M over that year. Dividing the one by the other, the reported balance equals about 3 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
Longevity Health Holdings (XAGE) has negative shareholder equity of -$5.9M as of fiscal year 2025, so no debt-to-equity or liabilities-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
Longevity Health Holdings (XAGE) has an Altman Z-Score of -56.92, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
Longevity Health Holdings (XAGE) has a Piotroski F-Score of 4 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Longevity Health Holdings (XAGE) reported a net loss of $6.9M while operations used $3.3M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Longevity Health Holdings (XAGE) reported an operating loss of $7.1M against $18K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.